Patients with heart valve disease are benefiting from advances over the past two years, including pivotal clinical trials, newly approved devices, and emerging technologies that expand treatment options for a range of valve conditions.
Transcatheter Aortic Valve Replacement (TAVR)
Asymptomatic severe aortic stenosis: Treating patients before symptoms develop represents a shift in TAVR indications. The EARLY TAVR trial found early intervention superior to clinical surveillance, reducing death, stroke, or unplanned cardiovascular hospitalization at two years. More than 30% of patients in the surveillance group developed advanced symptoms before valve replacement. Early TAVR was also associated with improved heart function. These findings challenge the traditional watchful waiting approach and support earlier identification of candidates.
Long-term durability: The PARTNER 3 and Evolut Low Risk trials showed TAVR is noninferior to surgical aortic valve replacement at five and six years for death and disabling stroke in low-risk patients. The NOTION trial, with 10-year follow-up, reported no significant difference in death, stroke, or myocardial infarction between TAVR and surgery. While slightly higher reintervention rates were noted with self-expanding valves, survival rates were similar.
Expanded use: Ongoing trials, including EXPAND TAVR II and PROGRESS, are evaluating TAVR in moderate and asymptomatic disease. Use has also expanded to more complex anatomy, including bicuspid valves, small annuli, and native aortic regurgitation with dedicated devices.
Transcatheter Mitral Valve Interventions
Transcatheter mitral valve replacement advanced with the ENCIRCLE trial in 2025, which evaluated the SAPIEN M3 system. The primary endpoint of death or heart failure hospitalization at one year was 25.2%, lower than the predicted 45% with medical therapy. Thirty-day mortality was 0.7% compared with a predicted 6.6%. At one year, 96% of patients had mild or less mitral regurgitation. The therapy offers a promising option for patients who are not candidates for surgery or transcatheter edge-to-edge repair.
Transcatheter edge-to-edge repair continues to expand, with more than 200,000 patients treated in national registries. For patients with mitral regurgitation who are high risk for surgery or have heart failure, the procedure has demonstrated strong safety and effectiveness when anatomy is suitable.
Transcatheter Tricuspid Valve Interventions
Tricuspid interventions have rapidly advanced as treatment options expand.
Transcatheter tricuspid valve replacement received FDA approval in February 2024 for the EVOQUE system. The TRISCEND II trial showed that replacement plus medical therapy reduced tricuspid regurgitation in more than 85% of patients and improved symptoms, including a 56.2-meter increase in six-minute walk distance.
Transcatheter tricuspid edge-to-edge repair has been validated in randomized trials. The Tri.Fr and TRILUMINATE Pivotal trials showed significant improvements in quality of life compared with medical therapy alone. Tricuspid regurgitation was reduced to moderate or less in 87% of patients. Greater reductions in disease severity were associated with greater improvements in quality of life.
LEARN MORE ABOUT NORTHSIDE HOSPITAL HEART INSTITUTE.
